Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment
Authors:
Open Access
- 1 February 2010
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 105 (4) , 502-507
Abstract
Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE: To determine, by post hoc analysis, the effects of tadalafil (a long‐acting phosphodiesterase 5 inhibitor) on peak urinary flow (Q max ), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH‐LUTS), compared with placebo. PATIENTS AND METHODS: After a 4‐week placebo run‐in period, 1058 men with BPH‐LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial. RESULTS: Increases in Q max were numerically greater for tadalafil (2.5, 5, 10, and 20 mg with percentage changes of 15%, 16%, 17%, 22%, respectively) vs placebo (12%), but did not reach statistical significance. Age, baseline Q max , erectile dysfunction history, sexual activity, and previous α‐blocker therapy significantly influenced the Q max response. Tadalafil was not associated with significant changes in PVR. Tadalafil had its greatest effects on bladder capacity and voiding efficiency in men with a Q max of max or voiding efficiency compared with placebo in men with BPH‐LUTS, although there were dose‐dependent improvements. No subgroups were identified where tadalafil or placebo treatment had a deleterious effect on Q max . Despite these minimal changes in uroflowmetric measures, tadalafil was associated with clinically meaningful and statistically significant improvements in the obstructive symptoms of BPH.Keywords
This publication has 20 references indexed in Scilit:
- TADALAFIL EXERTS AN ADDITIVE EFFECT ON ALFUZOSIN- INDUCED RELAXATION IN PRE-CONTRACTED HUMAN ISOLATED PROSTATIC ADENOMAJournal of Urology, 2008
- Vardenafil Improves Urodynamic Parameters in Men With Spinal Cord Injury: Results From a Single Dose, Pilot StudyJournal of Urology, 2007
- Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2007
- Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men With Erectile Dysfunction and Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Randomized, Double-Blind TrialJournal of Urology, 2007
- The Challenge of Subgroup Analyses — Reporting without DistortingNew England Journal of Medicine, 2006
- Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunctionBJU International, 2005
- Chronic Ischemia Increases Prostatic Smooth Muscle Contraction in the RabbitJournal of Urology, 2003
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- ‘Prostate‐related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptomsBritish Journal of Urology, 1994
- Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trialThe Prostate, 1990